DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Susoctocog alfa

Susoctocog alfa

  • Clinical Commissioning Policy: Susoctocog Alfa for Treating Bleeding Episodes in People with Acquired Haemophilia a (All Ages)

    Clinical Commissioning Policy: Susoctocog Alfa for Treating Bleeding Episodes in People with Acquired Haemophilia a (All Ages)

  • Human and Recombinat Coagulation Factor VIII

    Human and Recombinat Coagulation Factor VIII

  • Annual Report 2016

    Annual Report 2016

  • Therapeutics Advisory Group

    Therapeutics Advisory Group

  • Australian Public Assessment Report for Lonoctocog Alfa (Rch)

    Australian Public Assessment Report for Lonoctocog Alfa (Rch)

  • Dossier Zur Nutzenbewertung Gemäß § 35A SGB V

    Dossier Zur Nutzenbewertung Gemäß § 35A SGB V

  • Australian PI

    Australian PI

  • Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020

    Medicines/Pharmaceuticals of Animal Origin V3.0 November 2020

  • A Practical Approach to the Patient with Acquired Haemophilia a in Poland

    A Practical Approach to the Patient with Acquired Haemophilia a in Poland

  • Treatment of High-Risk Bleeding with Susoctocog Alfa in a Patient with Acquired Haemophilia a and a Nosocomial Severe Acute Resp

    Treatment of High-Risk Bleeding with Susoctocog Alfa in a Patient with Acquired Haemophilia a and a Nosocomial Severe Acute Resp

  • Obizur, INN Susoctocog Alfa

    Obizur, INN Susoctocog Alfa

  • Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review

    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review

  • Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

    Comparative Analysis of Legislative Requirements About Patients’ Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries

  • International Recommendations on the Diagnosis and Treatment of Acquired Ferrata Storti Foundation Hemophilia A

    International Recommendations on the Diagnosis and Treatment of Acquired Ferrata Storti Foundation Hemophilia A

  • Lists of Medicinal Products for Rare Diseases in Europe*

    Lists of Medicinal Products for Rare Diseases in Europe*

  • Recombinant Factor VIII: Past, Present and Future of Treatment of Hemophilia A

    Recombinant Factor VIII: Past, Present and Future of Treatment of Hemophilia A

  • Final Belgian List

    Final Belgian List

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

Top View
  • PRAC Draft Agenda of Meeting 23-26 November 2020
  • WFH Treatment Guidelines 3Ed Chapter 3 Laboratory
  • Prescribing Outlook Includes Such Drugs but Underpinning the Strategic Direction for Managing New Quantifying Their Impact Is Difficult
  • 3-6 July 2017 PRAC Meeting Minutes
  • ELOCTA, INN-Efmoroctocog Alfa
  • Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England
  • JAPC Annual Report 2016/2017
  • Repertorium 2019
  • CHMP December 2018 Agenda for Publication
  • (CHMP) Agenda for the Meeting on 21-24 June 2021
  • Exe Brochure Mds__2018 Versi
  • APC Monthly Update
  • Prescription Medicines and Biologicals: TGA Annual Summary 2016 Prescription Medicines and Biologicals: TGA Annual Summary 2016 Contents
  • Report Template
  • Obizur, INN Susoctocog Alfa
  • Scientific Programme Sunday, 12. July 2020 Plenary Session State-Of-The-Art on Hemophilia and Rare Bleeding Disorders State-Of-T
  • CHMP Agenda of the 25-29 January 2021 Meeting
  • WHO Drug Information Vol


© 2024 Docslib.org    Feedback